Dr.ALI ASGHAR EBRAHIMI
11-14June 2014 - French–Paris
|
I was participated inEular (European League Against Rheumatism)(11-14 June 2014)(French–Paris) congress with 13 other persons of Iranian colleagues (Rheumatologist). This Eular congress so as other previous annual Eulars was very extended, seriously and has many many truly on time sessions.
Key print from this Eular: -Some New monoclonal antibodies: Brodalumab (for PsoriaticArthrits) Remsimn(biosimilar Infliximab) for (AS) Ankylosing Spondylitis and Rheumatoid Arthrits(RA) , … -ChronicRheumatic Diseases so as RA must be manage with individualiseprogram(According to many diffident data(clinical , paraclinic and Personal or economic condithus of the patients). -The main aim of the TREAT of RHEUMATIC disease is : Retern the active Patients to Activity. With thanks Dr ALI ASGHAR EBRAHIMI( INTERNIST- RHEUMATOLOGIST) |